A UNIQUE OPPORTUNITY IN

ANIMAL HEALTH

JANUARY 2017

DISCLAIMER

This document has been prepared by Gour Medical SA (“the Company”) solely for use at this presentation. By receiving this presentation, you acknowledge that you have read the following restrictions. This document is confidential and is not to be reproduced by any person, nor to be distributed. Certain information contained in this presentation includes forward-looking statements. Forward-looking statements are not guarantees of future performance of Gour Medical SA and its actual financial condition, actual results of operations and cash flows and the development of the industry in which it operates may differ materially from those made in or suggested by the forward-looking statements contained in this presentation. In addition, even if Gour Medical SA’s financial condition, results of operations and cash flows and the development of the industry in which Gour Medical SA operates are consistent with the forward-looking statements contained in this presentation, those results or developments may not be indicative of results or developments in future periods. Gour Medical does not undertake, nor does it have any obligation, to provide updates or to revise any forward-looking statements to reflect events that occur or circumstances that arise after the date of this presentation. Gour Medical takes no responsibility for the use of this information by any person. The information contained in this presentation has not been subject to independent verification. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein. The information set out herein is subject to updating, completion, revision, verification and amendment and such information may change materially. Gour Medical is under no obligation to keep current the information contained in this presentation and any opinion expressed in them is subject to change without notice. Gour Medical shall have no liability whatsoever (in negligence or otherwise) for any loss arising from any use of this document or its contents or otherwise arising in connection with this document. It is not the purpose of this presentation to provide, and you may not rely on this presentation as providing, a complete or comprehensive analysis of Gour Medical’s financial or commercial position or prospects. This document does not constitute an offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any shares of Gour Medical in the United States or any other jurisdiction and nor any part of it shall form the basis of, or be relied upon in connection with, any contract, commitment or investment decision in relation thereto. In France, the offer of Gour Medical’s shares described above will take place solely as a private placement, in accordance with Article L. 411-2 of the Code monétaire et financier and applicable regulations. The offering does not constitute a public offering in France, as defined in Article L. 411-1 of the Code monétaire et financier and no prospectus reviewed or approved by the Autorité des marchés financiers will be published. The Company’s securities have not been, and will not be, registered under the United States Securities Act 1933 (the “Securities Act”), nor with any market authority within the United States. Therefore, the Company’s securities can not be offered, sold, distributed or otherwise transferred within the United States, nor on behalf of or for the benefit of U.S. persons except pursuant to an exemption from the registration requirements under the Securities Act or a registration under the Securities Act. This Presentation can not be distributed or transferred by anyone within the United States. In the United Kingdom, this presentation is directed only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the “Financial Promotion Order”), (ii) are persons falling within Articles 49(2)(a) to (d) (“High Net Worth Companies, Unincorporated Associations, etc”) of the Financial Promotion Order, (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of Section 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any shares may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as “Relevant Persons”). This presentation is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. This presentation is solely for your information on a confidential basis and may not be reproduced, redistributed or published (whether internally or externally to your company), directly or indirectly, in whole or in part, to any other person. Neither this document nor any copy of it may be taken, transmitted into or distributed in the United States of America, Canada, Australia, Japan or to any resident of these countries. The distribution of this document in other jurisdictions may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of applicable securities law.

2

ADVANCED CARE FOR MATURE PETS

OUR MISSION

GOUR Medical offers veterinarians a new way to support mature pets and their owners, with products designed for the specific needs of the older pet The range of products will address specific conditions and enable mature pets to benefit from the most advanced scientific innovations GOUR Medical makes it possible by investing in human-based R&D transferred to animal health

3

A GROWING MARKET WITH LARGE POTENTIAL FOR GOUR OFFER

4 Source : ERS - Healthcare Innovation – July 2015

0

20

40

TotalAnimalHealth

CompanionAnimals

MaturePets

conditions

GOURpotentialmarket

23.4

9.4 3.5 1

Turnover in 2014 / Estimates in USD Bn (worldwide)

5 Source Jefferies International Limited – June 2015 * Cumulative Annual Growth Rate (CAGR)

WHY INVEST IN ANIMAL HEALTH ?

9 9.4

13.5

0

2

4

6

8

10

12

14

16

Turnover CA 2013 Turnover CA 2014 Turnover CA 2020

Companion animals (CA) potential market (USD Bn) worldwide

CAGR* +6,2%

Mature pets 30% of total worldwide pets population*

• Mature pets require specific and regular medical care, as disease prevalence and chronic pathologies are higher in this population

Potential mature pets market for GOUR medical offer : USD 1 Bn

6

WHY INVESTING IN GOUR MEDICAL ?

*Source Aurgalys

OUR STRATEGIC POSITIONNING

7

GOUR IS UNIQUE BY COMBINING INNOVATION AND MATURE PETS TARGET

OUR BUSINESS MODEL

Looking for innovative solutions to improve mature pets’ health and life

License molecules through third parties

Develop products up to market readiness alone or with external partners

Commercialize products through external partners

8

ACQUISITION OF EXCLUSIVE LICENSES AND DISTRIBUTION RIGHTS FROM LEADING TECHNOLOGY PROVIDERS

A BALANCED PRODUCT PIPELINE

9

POC: proof-of-concept

GOUR-153:Pain / GOUR-713:Anxiety / GOUR 419:Atopy

10

Gour medical will sell to veterinary professionals via partnerships with distributors and animal health companies Control of distribution costs

Key countries at launch period will be:

France, UK, Germany, Italy and Spain

GO TO MARKET

HIGH QUALITY OPHTHALMIC LINE

TO CLEAN AND LUBRICATE EYES

GOUR peak annual sales :

> 3 M EUR

NEXT STEPS:

Re-confirm regulatory status in selected countries before products launch

Develop branding

Select commercial partners starting with France and UK as a first step

11

Examples only

GOUR-153 CANNABINOID BASED

(CBD) TO SUPPORT ANIMALS

SUFFERING FROM PAIN

12

GOUR peak annual sales :

> 10 M EUR

NEXT STEPS:

Compile submission and submit to EC Commission and the European Food Safety Authority

Ensure a consistent purity of the product in agreement with standards for registration as feed additive

GOUR-713 DUAL RECEPTOR ANTAGONIST

TO TREAT BEHAVIOR DISORDERS AND

ANXIETY

13

GOUR-713 peak annual sales :

> 13 M EUR

NEXT STEPS:

Based on product profile, support

the proof-of-concept work with regulatory input

Assess targeted claim of Gour-713 on canine

behaviour in laboratory and clinical studies

GOUR- 419 ANTI- IgE ANTIBODY TO

TREAT ATOPIC DERMATITIS IN

DOGS

14

GOUR peak annual sales :

> 60 M EUR

NEXT STEPS:

Confirm source of clinical material

Obtain scientific advice on POC study design

Produce material for POC study

Day - 30

Day 53

DEVELOPMENT STRATEGY

ACQUISITION OF NEW PRODUCTS

15

Targeted therapeutics areas:

Eyes and ears (dog and cat)

Orthopedic disorders (dog and cat)

Behavioral disorders (dog and cat)

Dental disease (dog and cat)

Cardiac diseases (dog)

Kidney disease/failure (cat)

…

EXECUTIVE TEAM

Serge Goldner: CEO. Former CFO at Immune Pharmaceuticals (NASDAQ:IMNP) and Managing Partner at Cukierman & Co. Life Sciences

Christian Bourgeois: Head of Operations. Former France subsidiary Director- Ceva Santé animale

Marie-Benedicte Charpentier: Head of Business Strategy and Development. Former Head of International Marketing – Companion Animals, Vetoquinol

Dr. Eva Bleul: Head of Regulatory Affairs. Former Head Regulatory Affairs Pharmaceuticals Europe, Novartis Animal Health

Jean Steffan: Head of Product Development. Former Senior Executive at Novartis AH

16

17

Daniel Denaud, DVM, Former VP Operations and Business strategies Pfizer

Animal Health Europe

Thierry Olivry, DrVet, PhD, Professor; veterinary immunodermatology and

allergy expert

Joël Besse, Former Managing Director of SED Ventures and a Managing

Partner of Atlas Venture, heading the European Life Sciences group.

ADVISORY BOARD

18

BOARD OF DIRECTORS

Serge Goldner: Chairman of the board Patrick Scherrer: Member of the board. Chairman of the board and co-

founder at G-ray Switzerland SA . Several investments in the technology and life-sciences sectors, including Actelion, Axovan, Endoart, immatics, Sensimed, Symetis, Evolva and Anergis.

Christian Grandjean: Member of the board. Managing Director of CMG Capital GmbH. Former Managing Director of Banque Cantonale Vaudoise, and CFO and COO of Christ Uhren & Schmuck AG

GOUR MEDICAL CAPTABLE

19

PRIVATE PLACEMENT

3.5M EUR

20

Ticker symbol: MLGML (Marché Libre Euronext Paris) ISIN: CH0342399851 Price Per Share (PPS) at listing: € 5.69 Total shares at listing: 2,830,000 Market cap at listing: 16.1M EUR Opening of the subscription period: December 5,2016

USE OF PROCEEDS

21

Commercial launch of Gour Ophthalmic line Gour-153 (pain) registration in Europe Gour-753 (behavior) POC Gour-419 (atopy) product development Up-list to Alternext Paris

SUBSTANTIAL NEWSFLOW TO COME 2017

22

Q3:First revenues from GOUR ophthalmology line Q3-Q4:Gour-153 (pain):Submission to EC

Commission Q3-Q4:Gour-713 (behavior):POC completion Q4:Gour-419 (Atopy): POC launch

GOUR PARTNERS

[ML-EURONEXT: MLGML]

Listing sponsor

Legal advisors

Equity research

Audit 23

GOUR MEDICAL ADVANCED CARE FOR MATURE PETS

A UNIQUE OPPORTUNITY TO SUCCEED!

Serge Goldner, CEO contact@gour-medical.com

Tel: +41 435 08 00 72